SCHEMBL23682935

SCHEMBL23682935

Cc1c(F)c(F)c(F)c(F)c1CC(N)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 8/20 0.46
GRIA3 P42263 8/20 0.46
GRIA4 P48058 7/20 0.46
GRIA2 P42262 5/20 0.46
GRIK5 Q16478 4/20 0.46
MAPT P10636 3/20 0.46
GRIK1 P39086 3/20 0.46
MEN1 O00255 3/20 0.46
CYP2C9 P11712 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C19 P33261 2/20 0.46
MAPK1 P28482 2/20 0.46
CYP1A2 P05177 1/20 0.46
TSHR P16473 1/20 0.46
GRIK2 Q13002 1/20 0.46
GRIK3 Q13003 1/20 0.46
GRIK4 Q16099 1/20 0.46
BLM P54132 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2971633 0.91 GRIA1 (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL2971635 0.91 GRIA1 (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL158168 0.86 MAPT (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL4626004 0.86 MAPT (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL43843 0.86 MAPT (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL11030460 0.78 GRIA1 (0.53) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL6046222 0.78 GRIA1 (0.53) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL5875640 0.78 GRIA1 (0.53) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL5283079 0.77 USP2 (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5
SCHEMBL5324038 0.77 USP2 (0.47) GRIA1GRIA3GRIA4GRIA2GRIK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, F13B, GRN GRIA1 1880/4885GRIA3 1651/4885GRIA4 2137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.